21:27 , Jun 27, 2019 |  BC Extra  |  Company News

Conserving cash, ImmunoGen to pursue narrower indication for bruised mirvetuximab

Immunogen is gutting its workforce and shelving at least two early stage programs to focus on the asset that put the biotech in this precarious position in the first place, antibody-drug conjugate mirvetuximab soravtansine. ImmunoGen...
19:19 , May 15, 2019 |  BC Extra  |  Company News

ImmunoGen looks to next Phase III after FDA rebuffs accelerated approval path for mirvetuximab

ImmunoGen plans to start a second Phase III trial before year end of mirvetuximab soravtansine that will focus on ovarian cancer patients with high FOLR1 expression after FDA told the company that data from a...
03:13 , Mar 29, 2019 |  BC Extra  |  Company News

Daiichi gets $1.35B up front from AZ in antibody-drug conjugate deal

AstraZeneca will pay Daiichi Sankyo $1.35 billion up front to bolster one of the four platforms of its oncology unit, ADCs. Daiichi Sankyo Co. Ltd. (Tokyo:4568) and AstraZeneca plc (LSE:AZN; NYSE:AZN) announced Friday that they...
02:21 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
18:23 , Mar 14, 2019 |  BC Extra  |  Financial News

TCG again backs Surrozen in $50M series B

Regenerative medicine company Surrozen raised a $50 Million series B round to move its optimized Wnt signaling mimetics into IND-enabling studies for an advanced liver disease yet to be determined. Surrozen Inc. (South San Francisco,...
17:28 , Mar 8, 2019 |  BC Week In Review  |  Clinical News

ImmunoGen down on Phase III ovarian cancer miss

ImmunoGen lost $2.21 (47%) to $2.51 on March 1 after reporting that mirvetuximab soravtansine missed the primary endpoint of improving progression-free survival (PFS) in the Phase III FORWARD I trial to treat FOLR1-positive, platinum-resistant ovarian...
18:24 , Mar 7, 2019 |  BC Innovations  |  Distillery Therapeutics

mir-515 inhibitor sensitizes HER2-negative breast and liver cancers to Kadcyla, Herceptin

DISEASE CATEGORY: Cancer INDICATION: Breast cancer; liver cancer In vitro and cell culture studies suggest an inhibitor of miR-515 could sensitize HER2-negative breast and liver cancers to anti-HER2 therapies. Chemical synthesis and in vitro testing...
20:29 , Mar 1, 2019 |  BC Extra  |  Clinical News

ImmunoGen down on Phase III ovarian cancer miss

ImmunoGen Inc. (NASDAQ:IMGN) lost $2.21 (47%) to $2.51 on Friday after reporting that mirvetuximab soravtansine missed the primary endpoint of improving progression-free survival (PFS) in the Phase III FORWARD I trial to treat FOLR1-positive, platinum-resistant...
03:20 , Feb 16, 2019 |  BioCentury  |  Product Development

ADCs’ inflection point

Industry is writing a new rule book for antibody-drug conjugates that could take the modality beyond the one-size-fits-all approach that has limited its success. By 2Q20, late-stage data from at least four ADCs testing new...
21:43 , Jan 18, 2019 |  BioCentury  |  Product Development

ImmunoGen’s milestone year

Nearly three years after refocusing the company to boost long-term value creation, ImmunoGen Inc. expects 2019 to be the year the changes will begin to bear fruit, starting with Phase III data from its lead...